Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, the market doesn’t seem to believe it…
I don’t think it’s fluffy at all. It’s a partnership in a country that’s growing very fast in the stem cell field.
I don’t care if some people perceive it as pumpy, it’s legit news so they need to promote themselves anyway possible.
Cause it’s fluffy crap that no one believes.
Indeed, it’s kind of a riddle though…. How do you do it without looking pumpy…. They’re posting all these articles to their website, and on their website, they aren’t even mentioning the stock, the parent company whatsoever. Overly cautious in my opinion, but put yourself in their shoes, if their plan was to do an honest SPAC, and they were excited about it, to the point they alerted thousands of investors and got their company suspended, what would you do with the new SPAC? Those folks received some fairly serious threats, on them and family…
All of this is great news but they still need to do something to get noticed and generate buying
All we need is A "Q" and this one is leaving the station! Pakistan express $$$
Dude, he took out massive debt so he wouldn’t get sued. Now he is posting on a discord?
Why hasn’t he announced this to the market?
Dave is seriously one of the biggest scum bags around.
The guy that gave back 8.2 million dollars to Laho shareholders? He’s there, doesn’t post much yet. One of your big complaints used to be that IR answers questions through email, now he answers them publicly and dislike that too…. Hmmm, tough crowd
Thanks for your lasting dedication here
Also, in no way shape or form waypoint would be considered a promo chat room, lol, looking at it once makes that obvious
Scum bag Dave on a public stock promo site?
Just getting started at Global stem Cell Group…. Footprint is expanding daily, multiple points of sales being established. Communication from the company about to get going. It’ll be nice to actually hear a game plan. Got a question for Dave? Ask him over at waypoint discord, it’s much better than emailing if he starts using it more like he plans.
Yet, per filings this shell cell company blows
Facebook pages
https://m.facebook.com/globalstemcells/
https://m.facebook.com/pages/category/Medical-Research-Center/issca.us/posts/
https://m.facebook.com/benitonovas2020
Lots of info on those pages, particularly global stem cells group and ISSCA pages
Here is MSSV’s official website from OTCmarkets…. There is a plethora of information there about what MSSV/Global stem cells group does.
http://mssvinc.com/
All in all, MSSV is a low float stock that has been silent for a very long time. Their reason for silence is not wanting to make the same mistakes as they did with LAHO(issue PRs while not being current).
Now that they are current, they are starting to open lines of communication, which at the current PPS, and OS, could be make for a lucrative trade
There are issues,
*their revenue is not very eye popping, need growth, which from Benito Novas’s Facebook, they have had a fairly large international marketing campaign for their stem cell services/products.
*due to the amazing feat of the LAHO buy back program, their balance sheet does not look good, which emphasizes their lack of revenue.
*the stock is completely off the radar from traders/investors, which will hopefully be remedied going forward with lines of communication being opened.
I think at this PPS, it’s a decent gamble with money that you can afford to lose. I think there is a good story to unfold here.
Waypoint is an IR that gives shareholders direct communications with CEO, gives shareholders the opportunity to ask questions and and get direct public responses. The main complaint there seems to be that the CEO has not been on there answering questions for most of the channels existence.
As far as LAHO goes, mistakes were obviously made. Main story is there, the note holders there converted 3 billion shares, netting $1.6 to $2 million, then got delisted, MSSV then came in and bought all the shares back for $8.2 million.
Because of LAHO, MSSV has been ultra careful with PRs, to the point where it has left traders/investors wondering if they are ever gonna communicate with shareholders. Seems the drought of info may be coming to an end, finally.
Waypoint has been working as their IR for about a year…. Unfortunately MSSV hasn’t utilized it much at all, they are now starting to get active. Investors have asked a few question on the QnA section, and evidently they did a video interview which they will put on waypoint’s YouTube.
Why would the CEO of MSSV post on a stock chat? Think about that…
Maybe ask him why they pump and dumped LAHO only to show how tiny this stem cell company really is…
Oh god! So not only is/was posting on iHub he now has his own discord to pump crap.
Nice find thanks
FYI for those that don’t know, MSSV has a discord channel on Waypoint Refinery. CEO Dave Christensen has started posting on there.
https://discord.gg/waypointrefinery
Nothing big, but it is a direct line for him to hear ya.
I don’t disagree for the most part, most of the bad has to do with paying back Laho SHs, but needed to see much more revenue. Hopefully this global campaign brings in some $’s
My bad. Was only looking at the news tab. Just checked sec and scanned them. Ugly.
What fins are they missing? They are current…..
Getting and staying current with financials would help also! Guess it is still too much to expect from Davey C.
Congratulations!!! No funds yet for my son. Since you just received yours, there is still hope.
Nice PR, I'm expecting a lot more but they still need to do something else to bring in buyers.
News, if anyone is still interested, supposedly the first of “many” PRs to come, also sounds like there will be a Question and answer YouTube with the CEO within the next month.
https://www.globenewswire.com/news-release/2022/06/27/2469406/0/en/Meso-Numismatics-and-Global-Stem-Cell-Group-Expand-its-Global-Footprint.html
If nothing else, could make for a nice swing
good news Slim! Now if they would just file the paperwork we could run again to 30c.
Anyone still holding shares of MSSV? No filings, no news, nothing from the company except silence. Can't even sell there are no buyers!
Sell the open and thank me later
You will definitely have to file a new form as it happened to me.
The escrow agents name is posted on the second page of chat on Laho board. It’s eilers or something or other. Law firm
Q1 revenue... 310,078
Net loss for Q-1 (1,676,964).
.14 a share loss
And another wonderful day at the Meso scam.
I totally agree with you!
Very strange that a small number of shares traded at .09 today while the bid was .04. I don’t like it, doesn’t make sense and is not reflective of the current demand for the stock.
Followers
|
343
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
50890
|
Created
|
01/07/08
|
Type
|
Free
|
Moderators |
LAS VEGAS, NV, Feb. 05, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Meso Numismatics, Inc. (“Meso Numismatics” or the “Company”) (MSSV), a regenerative medicine company is pleased to announce that it will be undergoing a name change from Meso Numismatics Inc. to Regenerative Medical Technology Group Inc. to better reflect the company’s business. The Company will also change its authorized shares outstanding from the current 6.5 billion to 100 million shares. Please see the Information Statement on Schedule 14C filed by the Company on February 2, 2024, and other Company filings at www.sec.gov.
About Meso Numismatics: Meso Numismatics Corp is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group. The Company currently has a network of 26 clinics in 21 countries that carry its banner and has its own clinic in Cancun and is currently building another one in Dubai. The Company distributes stem cells and other regenerative based cell lines, and equipment internationally and also specializes in education and training physicians in the area of regenerative medicine.
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
Forward-Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words “plan”, "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Lans Holdings Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
Investor.relations@mssvinc.com
Telephone: (800) 956-3935
The Cancun clinic is currently active and is finalizing its full build out, which will double its footprint by the end of February. The clinic is also comprised of a lab where stem cell cultures can be produced. The Cancun clinic currently offers numerous procedures for multiple indications including: hormone replacement, autoimmune, neurodegenerative, osteoarthritis, cardiovascular, aesthetic/anti-aging, hair transplant, sports medicine, spinal cord injury, MS, and autism. The Company is in the process of building out a clinic in Dubai that will offer similar procedures to those in the Cancun location. The Dubai clinic is expected to be fully operational by the end of the second quarter of this year.
The Company plans to close on two additional locations for new clinics, one by the end of the third quarter and one by the end of the fourth quarter of this year. Both of these clinics are expected to be operational by the end of the second quarter of 2025.
The Company also has a collaboration with an Istanbul based clinic where the Company refers patients and receives patient referrals on various patient procedures.
The Company operates in the stem cell therapy market, which is expected to grow from $11.2 billion in 2022 to $31.4 billion by 2030 according to Precedence Research. The Company has also entered the exosome market, which is expected to grow from $250 million in 2022 to $3.2 billion by 2032 according to Global Market Insights.
The Company is actively collaborating with leading research institutions, universities, and industry experts to accelerate the development and commercialization of regenerative medical solutions. These partnerships create a collaborative ecosystem that fosters scientific excellence and ensures that the Company remains at the forefront of innovation, contributing to medical advancements and expanding its range of products. With a global vision, the Company is dedicated to making a positive impact on healthcare worldwide. The company is exploring opportunities to expand its reach and make its cutting-edge medical procedures accessible to patients across borders.
"We are thrilled to be at the forefront of regenerative medicine, bringing hope to patients and pushing the boundaries of what is possible in biotechnology. Our commitment to innovation and collaboration underscores our mission to make a lasting impact on the lives of individuals facing challenging medical conditions," said David Christensen, CEO and President of the Company.
The driving forces behind Global Stem Cells Group's strategy to increase revenue in 2024 involve a multifaceted approach within the rapidly expanding stem cell therapy market. As the wholly-owned subsidiary of the Company, Global Stem Cells Group specializes in cutting-edge stem cell research collaborations and physician training. The key components contributing to revenue growth include:
Certified Training Courses for Physicians - Offering specialized and certified training courses to physicians, ensuring they are equipped with the latest knowledge and skills in stem cell therapies. The Company is internationally recognized as an expert in the field of stem cells and regenerative medicine.
Manufacturing and Sales of the Latest Technology, Supplies, and Equipment - Engaging in the production and sale of state-of-the-art technology, supplies, and equipment related to stem cell applications, catering to the needs of medical professionals in the field.
Research and Development of Clinical Protocols - Investing in research and development collaborations to create advanced clinical protocols for stem cell applications, enhancing the efficacy and safety of treatments.
Regenerative Medical Clinics - Cancun, Dubai, and Istanbul, Provide standardized regenerative medical treatments. These treatments cover a spectrum of health issues, including musculoskeletal disorders, autoimmune diseases, aesthetics, and anti-aging.
Franchising Network of Regenerative Medical Practitioners - Establishing a network of franchised regenerative medical practitioners, potentially increasing the geographical reach and accessibility of stem cell treatments. Currently 26 clinics in 21 countries carry the Company's banner. This allows the Company to raise its global profile and branding and assist the company in bringing patients to its own clinics.
Turnkey Solutions for Stem Cell Processing Center Installation & Management - Offering comprehensive complete solutions for the installation and management of stem cell processing centers, providing a one-stop solution for practitioners entering the field.
By diversifying into these key areas Global Stem Cells Group aims to tap into various aspects of regenerative medicine, creating revenue streams through education, product sales, research, patient services, and strategic partnerships within the stem cell therapy market.
"We are excited to announce our significant growth across multiple channels, showcasing the strength and diversity of our business. The success in training, product sales, equipment sales, and patient procedures reflects our commitment to excellence in every facet of regenerative medicine," said Benito Novas, CEO and Founder of Global Stem Cells Group.
This press release should be read in conjunction with all of the Company's filings on www.sec.gov
About Meso Numismatics: Meso Numismatics, Inc. is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group. The Company currently has a network of 26 clinics in 21 countries that carry its banner and has its own clinic in Cancun and is currently building another one in Dubai. The Company distributes stem cells and other regenerative based cell lines and equipment internationally and also specializes in educating and training physicians in the area of regenerative medicine.
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
Forward Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Lans Holdings Inc., herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Lans Holdings Inc. disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
For further information, please contact:
Investor.relations@mssvinc.com
Telephone: (800) 956-3935
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |